These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26123071)

  • 1. Can we rely on lymphovascular invasion for determining the need for adjuvant chemotherapy in organ-confined bladder cancer?
    Gakis G; Stenzl A
    BJU Int; 2015 Jul; 116(1):3-4. PubMed ID: 26123071
    [No Abstract]   [Full Text] [Related]  

  • 2. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial.
    von Rundstedt FC; Mata DA; Groshen S; Stein JP; Skinner DG; Stadler WM; Cote RJ; Kryvenko ON; Godoy G; Lerner SP
    BJU Int; 2015 Jul; 116(1):44-9. PubMed ID: 25413313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
    Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
    J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for induction therapy for locally advanced bladder cancer?
    Soloway MS
    Urology; 1987 Jun; 29(6):577-83. PubMed ID: 3576880
    [No Abstract]   [Full Text] [Related]  

  • 5. Perioperative chemotherapy for invasive bladder cancer--what should we tell our patients?
    Raghavan D
    J Urol; 1996 Apr; 155(4):1246-7. PubMed ID: 8632541
    [No Abstract]   [Full Text] [Related]  

  • 6. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of systemic chemotherapy in advanced bladder cancer.
    van Groeningen CJ; Stoter G
    Prog Clin Biol Res; 1984; 153():381-93. PubMed ID: 6382283
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapy for metastatic bladder cancer.
    Kantoff PW; Scher HI
    Hematol Oncol Clin North Am; 1992 Feb; 6(1):195-203. PubMed ID: 1556050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer.
    McHugh LA; Griffiths TR; Kriajevska M; Symonds RP; Mellon JK
    Urology; 2004 Apr; 63(4):619-24. PubMed ID: 15072863
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of apoptotic antitumor effect between angiogenesis inhibitor AGM-1470 and MVAC chemotherapy on rat urinary bladder cancer.
    Sejima T; Isoyama T; Miyagawa I
    Urol Int; 2004; 73(3):226-33. PubMed ID: 15539841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy of bladder tumors].
    Vallet D; Cappelaere P; Adenis L; Demaille A
    Lille Med; 1978; 23(7):486-9. PubMed ID: 364222
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
    Lehmann J; Retz M; Stöckle M
    World J Urol; 2002 Aug; 20(3):144-50. PubMed ID: 12196897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic therapy of bladder cancer.
    Salem PA
    Prog Clin Biol Res; 1984; 162B():95-105. PubMed ID: 6209726
    [No Abstract]   [Full Text] [Related]  

  • 16. [Neoadjuvant chemotherapy with MVAC in bladder carcinoma: Is the feasibility really established? Of: Benadiba et al.: Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences on cystectomy, Pr Urol 2015; 25: 549-554].
    Coquard R
    Prog Urol; 2015 Dec; 25(16):1171-2. PubMed ID: 26420677
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial.
    Ye JJ; Ren SQ; Bao YG
    Asian J Surg; 2023 Feb; 46(2):1163-1164. PubMed ID: 36088195
    [No Abstract]   [Full Text] [Related]  

  • 18. The chemotherapy of bladder carcinoma: systemic therapy.
    Harker WG; Torti FM
    Recent Results Cancer Res; 1983; 85():37-49. PubMed ID: 6408717
    [No Abstract]   [Full Text] [Related]  

  • 19. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].
    Matveev BP; Figurin KM
    Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.